Related Experiment Video

Updated: May 27, 2026

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain
06:31

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain

Published on: August 8, 2019

Suzetrigine for Cancer-Related Bone Pain: A Three-Patient Case Series

Jamal Hasoon1, Anvinh Nguyen2, Ranganathan Govindaraj3

  • 1Department of Anesthesiology, Critical Care, and Pain Medicine The University of Texas Health Science Center at Houston.

Orthopedic Reviews
|May 26, 2026
PubMed

Insights

Suzetrigine, a novel non-opioid analgesic, showed no significant pain relief in three patients with advanced cancer-related bone pain. The study highlights potential limitations for opioid-tolerant patients.

Area of Science:

  • Oncology
  • Pain Management
  • Pharmacology

Background:

  • Cancer-related bone pain is a significant clinical issue, especially in metastatic disease.
  • Conventional therapies are often insufficient for advanced cases.
  • Suzetrigine, a NaV1.8 inhibitor, is a potential non-opioid analgesic for pain states.

Purpose of the Study:

  • To evaluate the efficacy of suzetrigine in patients with advanced cancer-related bone pain.
  • To assess suzetrigine's utility in opioid-tolerant patients with metastatic spinal cancer.

Main Methods:

  • A case series of three patients with metastatic spinal cancer experiencing bone pain.
  • Patients underwent a three-week trial of suzetrigine.
  • Pain improvement and adverse effects were monitored.

Main Results:

  • No meaningful pain improvement was observed in any of the three patients during the trial.
  • Treatment was discontinued due to lack of efficacy.
  • Cost was a factor in discontinuation for one patient.
  • No adverse effects were reported.

Conclusions:

  • Suzetrigine demonstrated limited efficacy in this small case series of advanced cancer-related bone pain.
  • Its utility may be restricted in opioid-tolerant patients.
  • Further research is needed to define suzetrigine's role in cancer pain management.
Keywords:
Suzetriginechronic pain managementmetastatic cancer painnon-opioid analgesicsspinal metastases

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...